Kineta, Inc. stock is down -50.19% since 30 days ago. The next earnings date is Apr 1, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 12.5% of the previous 8 February’s closed higher than January.
Yumanity Therapeutics Inc. engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson's disease and related disorders of a-synuclein.
Unlock Exclusive Market Insights! Receive timely updates on market developments. Sign up & stay informed!